New Gene-Switching Cancer Therapy Emerges

Monash and Harvard researchers have achieved a groundbreaking epigenetic discovery, finding a way to permanently "switch off" cancer-causing genes, which promises shorter treatment durations and reduced severe side effects for patients. This innovative therapy targets specific proteins in aggressive acute leukemia cells, with clinical trials anticipated to begin later this year.